Nycomed Gmbh

Takeda Gmbh

Byk Gulden Lomberg Chemische Fabrik Gmbh

Altana Pharma Ag

Hans-Peter Kley

Beate Schmidt

Geert Jan Sterk

Raimund Kuelzer

Dieter Flockerzi

Armin Hatzelmann

Degenhard Marx

Christof Zitt

Hermann Tenor

Andrea Wohlsen

Anke Heuser

Rolf-Peter Hummel

Christian Scheufler

Steffen Weinbrenner

Martin Feth

Raimund Külzer

Wiro M P B Menge

Johannes A M Christiaans

Deborah Ockert

Ulrich Kautz

Klaus Eistetter

Guido Hanauer

Clemens Braun

Wilhelm Wurst

Jens Christoffers

Anna Rosiak

Juergen Volz

Daniela Hauser

Imre Schlemminger

Jürgen Volz

Hartmann Schaefer

Karl Sanders

Anna Christoffers

Dirk Bredenbröker

Thomas Klein

Dirk Bredenbroeker

Joerg Kemkowski

Heinz-Gunter Menge

Jörg Kemkowski

Maria Vittoria Chiesa

Jens Prof Dr Christoffers

Martin P Feth

Raimund c/o Nycomed Gmbh Külzer

Johannes Barsig

Wiro MPB Menge

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.

Roflumilast for the treatment of diabetes mellitus type 2

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof.

Combination of a NSAID and a PDE-4 inhibitor

The compounds of formula (I) in which R1, R2 and R3 have the meanings as given in the description are novel effective PDE2 inhibitors.

Triazolophthalazines

The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.

Roflumilast for the treatment of diabetes mellitus

The compounds of formula I in which R1 and R2 have the meanings as given in the description are novel effective PDE2 inhibitors.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

The invention relates to the use of certain known PIDE4 inhibitors for the treatment of diabetes mellitus and accompanying disorders thereof.

Use of PDE4 inhibitors for the treatment of diabetes mellitus

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

The invention relates to the novel use of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide, a pharmacologically tolerable salt thereof or its N-oxide in the treatment of multiple sclerosis.

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis

Growing community of inventors

Allensbach, Germany

Hans-Peter Kley